Rocio Vallejo-Montero

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Journal: United European gastroenterology journal

Published: July 17, 2023

Novel insights into metabolic-associated steatotic liver disease preclinical models.

Novel insights into metabolic-associated steatotic liver disease preclinical models.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 13, 2023

Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.

Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.

Journal: European cardiology

Published: May 26, 2023

Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.

Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 17, 2023

Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis.

Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis.

Journal: Biomarker research

Published: January 03, 2023

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients.

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients.

Journal: International journal of molecular sciences

Published: September 07, 2022

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool.

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool.

Journal: Biomarker research

Published: April 13, 2022

Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma.

Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: June 09, 2021

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.

Journal: Journal of hepatology

Published: March 18, 2021

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Journal: Scientific reports

Published: March 12, 2021

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Journal: Frontiers in immunology

Published: February 12, 2021

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study.

Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study.

Journal: Clinical and translational gastroenterology

Published: September 21, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026